Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

146.92USD
18 Jan 2018
Change (% chg)

$-0.06 (-0.04%)
Prev Close
$146.98
Open
$146.93
Day's High
$147.44
Day's Low
$145.99
Volume
1,918,039
Avg. Vol
1,924,990
52-wk High
$148.32
52-wk Low
$110.76

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

18 Jan 2018

Deals of the day-Mergers and acquisitions

Jan 17 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:

18 Jan 2018

Exclusive: J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal - sources

HONG KONG Chinese bidders are circling a diabetes care business owned by the world's largest healthcare company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters.

17 Jan 2018

Exclusive: J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal - sources

HONG KONG Chinese bidders are circling a diabetes care business owned by the world's largest healthcare company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters.

17 Jan 2018

Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit

A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson & Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.

10 Jan 2018

Bayer, J&J win reversal of $28 mln verdict in Xarelto lawsuit

Jan 9 A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson & Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.

10 Jan 2018

Analysis: $11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion (8.12 billion pounds) burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

$11 billion biotech binge fuels forecasts of 2018 M&A surge

LONDON An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.

08 Jan 2018

FDA issues recall on J&J heart device

The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve, following a recall by the company in June.

04 Jan 2018

Earnings vs. Estimates